MARKET

PEPG

PEPG

PepGen Inc
NASDAQ
14.71
+0.62
+4.40%
Opening 15:19 03/28 EDT
OPEN
14.00
PREV CLOSE
14.09
HIGH
14.90
LOW
14.00
VOLUME
19.56K
TURNOVER
0
52 WEEK HIGH
17.51
52 WEEK LOW
3.720
MARKET CAP
475.93M
P/E (TTM)
-4.4519
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PEPG last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at PEPG last week (0311-0315)?
Weekly Report · 03/18 09:03
PepGen to Participate in Upcoming Investor Conferences
PepGen Inc. Management will participate in the following upcoming investor conferences. PepGen is a clinical-stage biotechnology company advancing the treatment of severe neuromuscular and neurological diseases. The company will be attending the following investor conferences:  
Barchart · 03/13 15:05
PepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51
NASDAQ · 03/13 12:05
PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations
PepGen has received the FDA's orphan drug and rare pediatric disease designations for its experimental therapy for Duchenne muscular dystrophy patients. PGN-EDO51 received the designations to treat the rare genetic disorder. The company is assessing the experimental therapy in the ongoing Phase 2 trial.
Dow Jones · 03/13 11:27
3 Best Stocks to Buy Now, 3/12/2024, According to Top Analysts
TipRanks · 03/12 10:09
Stifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)
TipRanks · 03/12 02:15
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 03/11 16:00
More
About PEPG
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Webull offers PepGen Inc stock information, including NASDAQ: PEPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEPG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEPG stock methods without spending real money on the virtual paper trading platform.